Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise

SynAct Pharma AB

27/05/2026 06:39

Overview
Sweden biotech firm reported no interim Q1 group's net sales and a wider net loss yr/yr
Interim operating expenses for Q1 rose 9% compared to last year
Company completed directed share issue and advanced multiple Phase 2 studies during quarter

Outlook
SynAct Pharma did not provide specific financial guidance for the current qtr or full yr

Result Drivers
SHARE ISSUE - Directed issue of new shares raised about SEK 51.9 mln, strengthening cash position

Company press release: ID:nMFN9BD2dN

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Group’s net Sales
 
SEK 0
 
Q1 Adjusted EPS
 
-SEK 0.48
 
Q1 Net Income
 
-SEK 25.49 mln
 
Q1 Cash Flow From Operating Activities
 
-SEK 32.95 mln
 
Q1 Operating Expenses
 
SEK 30.56 mln
 

Analyst Coverage
Wall Street's median 12-month price target for SynAct Pharma AB is SEK30.00, about 108.6% above its May 26 closing price of SEK14.38

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)